Tryton Announces First Implants in Israel

DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to
definitively treat bifurcation lesions, announced that the company’s
TRYTON Side Branch Stent™ System has been used in three cases in Israel
for the first time.

Yaron Almagor, M.D., director of the Interventional Cardiology and
Cardiac Catheterization Laboratories at Shaare Zedek Medical Center in
Jerusalem, Israel, performed the first implants.

“I am very pleased with the Tryton Stent System,” said Dr. Almagor.
“Recently I had successful outcomes treating two patients with cases of
complex true bifurcations – including one with left main disease, which
can be very difficult to treat. I look forward to utilizing the Tryton
stent to treat complex cases when it becomes commercially available for
use in Israel.”

Left main disease, an accumulation of plaque that narrows the base of
the coronary tree, until recently has been treated with bypass surgery.
Recent studies have demonstrated that stents may provide physicians and
patients with an important alternative. Widespread adoption of stenting
for left main disease has been hampered by the lack of a robust strategy
for bifurcations lesions, which represent more than 75 percent of left
main lesions. A Tryton strategy for left main disease has the potential
to provide an important tool as stenting becomes established as a
standard treatment for left main disease.

Professor Ran Kornowski, M.D., director of Interventional Cardiology at
Rabin Medical Center and Tel Aviv University, who also participated in
the first two cases and also performed a case in his hospital, added,
“Based on our first successful experiences, the Tryton stent seems to be
an important new tool for interventionists as we take on cases involving
complex bifurcations and the distal segment of the left main coronary
artery.”

“Bifurcation disease remains one of the last frontiers in treating
coronary artery disease. The Tryton stent system – which has now been
utilized to treat more than 1,300 patients – offers an innovative
solution for these challenging cases. We are pleased that the Tryton
solution will soon be available to clinicians and patients in Israel,”
said J. Greg Davis, president and CEO of Tryton Medical.

The Tryton Stent System is currently in the process of obtaining
regulatory approvals in Israel. The first three implants were performed
under a special exemption approval by the Ministry of Health.

About the Tryton Side Branch Stent System

The Tryton Side Branch Stent System is designed to offer a dedicated
strategy for treating atherosclerotic lesions in the side branch at the
site of a bifurcation. Tryton’s highly deliverable cobalt chromium stent
is deployed in the side branch artery using a standard single-wire
balloon-expandable stent delivery system. A conventional drugeluting
stent is then placed in the main vessel.

The Tryton Side Branch Stent System demonstrated excellent six-month
clinical results in a first-in-man study of the system in 30 patients,
with no restenosis occurring in the side branch artery. The stent system
has received CE Mark approval in Europe and is commercially available in
Austria, Belgium, Denmark, Ireland, Italy, Luxembourg, the Netherlands,
Norway, Poland, Portugal, Spain, and the United Kingdom. It is not
approved in the United States.

About Tryton Medical, Inc.

Tryton Medical, Inc., located in Durham, N.C., is a leading developer of
novel stent systems for the treatment of bifurcation lesions. The
company`s Side Branch Stent System, approved for sale in Europe, is
designed to offer a dedicated strategy for treating these challenging
cases. The privately held company is backed by Spray Ventures, PTV
Sciences, and RiverVest Ventures. For more information please visit trytonmedical.com.